Allarity Therapeutics Inc. Common Stock (ALLR)
Stock · NASDAQ · Health Care
$0.8593as of 10/16/2026
Price chart
Active signals
ALLR Signal Track Record
How signals performed across all stocks →What ALLR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 22 | -20.3% | 14% | September 8, 2026 |
| Volume Spike | 21 | -8.7% | 38% | September 17, 2026 |
| Bollinger Band Breakout | 12 | -4.6% | 42% | August 4, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -4.4% | 38% | September 8, 2026 |
| Any 20-session window (baseline) | -16.9% | 25% |
Computed by MarketWall from daily closing prices since October 6, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ALLR
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is sten…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 7
- Website
- allarity.com/
Fundamentals
- 1-day range
- $0.8$0.8999
- Market cap
- $21.65M
- P/E (trailing)
- —
- P/E (forward)
- -0.97
- EPS (trailing)
- $-0.79
- Dividend yield
- —
- Beta
- 0.60
- Avg. volume
- 96.0K
How Allarity Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 30, 2026 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Allarity Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ALLRAllarity Therapeutics Inc. Common Stock$0.895▲ 7.44%Market cap $21.65MP/E —$0.769$1.84
- CALCCalciMedica Inc. Common Stock$1.04▼ 3.70%Market cap $21.88MP/E —$1.27$36
- NEUPNeuphoria Therapeutics Inc. Common Stock$3.3▼ 0.30%Market cap $21.08MP/E —$3.19$17.9
- ATOSAtossa Therapeutics Inc. Common Stock$2.91▲ 9.81%Market cap $20.84MP/E —$1.7$16.5
- QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares$2.47▼ 8.86%Market cap $20.67MP/E —$2.85$23.1
- OBXObsidian Therapeutics Inc. Common Stock$11.77▼ 3.52%Market cap $22.74MP/E —$11.79$49.97
- TVRDTvardi Therapeutics Inc. Common Stock$1.01▼ 5.61%Market cap $23.02MP/E —$0.93$7.23
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ALLR Allarity Therapeutics Inc. Common Stock | $21.65M | — | $0.895 | ▲ 7.44% | $0.769$1.84 |
| CALC CalciMedica Inc. Common Stock | $21.88M | — | $1.04 | ▼ 3.70% | $1.27$36 |
| NEUP Neuphoria Therapeutics Inc. Common Stock | $21.08M | — | $3.3 | ▼ 0.30% | $3.19$17.9 |
| ATOS Atossa Therapeutics Inc. Common Stock | $20.84M | — | $2.91 | ▲ 9.81% | $1.7$16.5 |
| QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares | $20.67M | — | $2.47 | ▼ 8.86% | $2.85$23.1 |
| OBX Obsidian Therapeutics Inc. Common Stock | $22.74M | — | $11.77 | ▼ 3.52% | $11.79$49.97 |
| TVRD Tvardi Therapeutics Inc. Common Stock | $23.02M | — | $1.01 | ▼ 5.61% | $0.93$7.23 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Allarity Therapeutics Highlights DRP Technology, Patent And Lab Advances To Support Stenoparib Development And Partnershipsbenzinga · 9/30/2026
- Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For WednesdayBenzinga · 9/16/2026
- Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11Benzinga · 9/16/2026
- Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib DevelopmentYahoo · 9/15/2026
- Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration StatementYahoo · 9/11/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 875.7K
- Total value held
- $954.5K
- Institutional holders
- 13
- Unknown228.1K
- Unknown190.4K
- Unknown171.8K
- Unknown137.6K
- Unknown48.1K
- Unknown29.0K
- Unknown27.5K
- Unknown23.2K
- Unknown12.3K
- Unknown7.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Allarity Therapeutics expands lab capabilities and highlights DRP technology
Allarity reported progress on its Drug Response Predictor platform, noting its role in advancing the clinical development of Stenoparib. The company also announced that its in‑house laboratory now includes proteomics and cell‑line research capabilities. These updates are intended to strengthen the drug development program and support existing partnerships. The stock remains near the lower end of its 52‑week price range.
Allarity Therapeutics expands lab capabilities and highlights DRP technology. Allarity reported progress on its Drug Response Predictor platform, noting its role in advancing the clinical development of Stenoparib. The company also announced that its in‑house laboratory now includes proteomics and cell‑line research capabilities. These updates are intended to strengthen the drug development program and support existing partnerships. The stock remains near the lower end of its 52‑week price range.